Fennec Pharmaceuticals

Home » Fennec Pharmaceuticals

Secondary

Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc., is a specialty pharmaceutical company focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric patients.

Symbol

FENC

Last Closing Price
$8.99

Shares
2,350,000

Effective Date
December 8, 2017

Underwriters
Wedbush PacGrow

To view the prospectus for Fennec Pharmaceuticals, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253